View Clinical Trial (Medical Research Study)

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia - NCT00833976-02114(Clinical Trial 268975)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Boston
State:  
MA
Zip Code: 02114
Conditions: High Triglycerides and Cholesterol
Purpose: This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication. The investigators hypotheses are that patients who receive Lovaza will experience a significant decrease in triglycerides from baseline. Secondary hypotheses include: Patients will experience a significant decrease in total cholesterol, and Lovaza will be well tolerated.
Study summary:
Criteria: Inclusion Criteria: 1. Female or male patients, 18-75 years of age. 2. Serum triglycerides > 200 mg/dl or high cholesterol 3. Current use of a atypical (second-generation) antipsychotic medication - including clozapine (Clozaril), olanzapine (Zyprexa), risperidone (Risperdal), aripiprazole (Abilify), ziprasidone (Geodon), quetiapine (Seroquel), paliperidone (Invega) - for at least three months Exclusion Criteria: 1. Current use of triglyceride or cholesterol-lowering medication 2. Current use of omega-3 fatty acid supplement 3. Intake of fish more than twice per week 4. Currently pregnant, or breastfeeding 5. Known hypersensitivity or allergy to omega-3 fatty acids (or any fish allergies) 6. Current use of anticoagulant medication, except for 1 baby aspirin/day - 81mg (coumadin, heparin, Plavix. etc). 7. Consumption of alcohol greater than two drinks per day or active substance abuse 8. Any medical condition that would make participation in the study unsafe, as determined by investigator
Study is available at: Massachusetts General Hospital
Boston, MA 02114
United States

Primary Contact:
Suzanna Fowler
Email: skfowler@partners.org
Phone: 617-726-2912

Secondary Contact:
Suzanna Fowler
Email: skfowler@partners.org
Phone: 617-726-2912
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.